128 related articles for article (PubMed ID: 37858540)
1. Mass cytometry as a tool in target validation and drug discovery.
Watson ECR; Baker W; Ahern D; Loi D; Cribbs AP; Oppermann U
Methods Enzymol; 2023; 690():541-574. PubMed ID: 37858540
[TBL] [Abstract][Full Text] [Related]
2. Barcoding of live human peripheral blood mononuclear cells for multiplexed mass cytometry.
Mei HE; Leipold MD; Schulz AR; Chester C; Maecker HT
J Immunol; 2015 Feb; 194(4):2022-31. PubMed ID: 25609839
[TBL] [Abstract][Full Text] [Related]
3. Immunophenotyping of Human Peripheral Blood Mononuclear Cells by Mass Cytometry.
Heck S; Bishop CJ; Ellis RJ
Methods Mol Biol; 2019; 1979():285-303. PubMed ID: 31028645
[TBL] [Abstract][Full Text] [Related]
4. High-throughput mass cytometry staining for deep phenotyping of human natural killer cells.
Ben Amara A; Rouviere MS; Fattori S; Wlosik J; Gregori E; Boucherit N; Bernard PL; Nunès JA; Vey N; Luche H; Gorvel L; Olive D; Chretien AS
STAR Protoc; 2022 Dec; 3(4):101768. PubMed ID: 36269638
[TBL] [Abstract][Full Text] [Related]
5. Establishing CD19 B-cell reference control materials for comparable and quantitative cytometric expression analysis.
Wang L; Bhardwaj R; Mostowski H; Patrone PN; Kearsley AJ; Watson J; Lim L; Pichaandi J; Ornatsky O; Majonis D; Bauer SR; Degheidy HA
PLoS One; 2021; 16(3):e0248118. PubMed ID: 33740004
[TBL] [Abstract][Full Text] [Related]
6. Development of a robust flow cytometry-based pharmacodynamic assay to detect phospho-protein signals for phosphatidylinositol 3-kinase inhibitors in multiple myeloma.
Li C; Takahashi C; Zhang L; Huseni M; Stankovich B; Mashhedi H; Lee J; French D; Anderson JE; Kim D; Howell K; Brauer MJ; Kowanetz M; Yan Y; Humke E; Ebens A; Hampton G; Lackner MR; Hegde P; Jia S
J Transl Med; 2013 Mar; 11():76. PubMed ID: 23522020
[TBL] [Abstract][Full Text] [Related]
7. Multiplexed mass cytometry profiling of cellular states perturbed by small-molecule regulators.
Bodenmiller B; Zunder ER; Finck R; Chen TJ; Savig ES; Bruggner RV; Simonds EF; Bendall SC; Sachs K; Krutzik PO; Nolan GP
Nat Biotechnol; 2012 Sep; 30(9):858-67. PubMed ID: 22902532
[TBL] [Abstract][Full Text] [Related]
8. Broad Immune Monitoring and Profiling of T Cell Subsets with Mass Cytometry.
Brodie TM; Tosevski V
Methods Mol Biol; 2018; 1745():67-82. PubMed ID: 29476463
[TBL] [Abstract][Full Text] [Related]
9. Exploring Glucocorticoid Receptor Agonists Mechanism of Action Through Mass Cytometry and Radial Visualizations.
Abraham Y; Gerrits B; Ludwig MG; Rebhan M; Gubser Keller C
Cytometry B Clin Cytom; 2017 Jan; 92(1):42-56. PubMed ID: 27933748
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of measurable residual disease in multiple myeloma by multiparametric flow cytometry: Current paradigm, guidelines, and future applications.
Soh KT; Wallace PK
Int J Lab Hematol; 2021 Jul; 43 Suppl 1():43-53. PubMed ID: 34288449
[TBL] [Abstract][Full Text] [Related]
11. Flow Cytometry-Based Photodynamic Diagnosis with 5-Aminolevulinic Acid for the Detection of Minimal Residual Disease in Multiple Myeloma.
Iwaki K; Fujiwara T; Ito T; Suzuki C; Sasaki K; Ono K; Saito K; Fukuhara N; Onishi Y; Yokoyama H; Fujimaki S; Tanaka T; Tamura H; Fujiwara M; Harigae H
Tohoku J Exp Med; 2019 Sep; 249(1):19-28. PubMed ID: 31511451
[TBL] [Abstract][Full Text] [Related]
12. High-Throughput Mass Cytometry Staining for Immunophenotyping Clinical Samples.
Thrash EM; Kleinsteuber K; Hathaway ES; Nazzaro M; Haas E; Hodi FS; Severgnini M
STAR Protoc; 2020 Sep; 1(2):100055. PubMed ID: 33111099
[TBL] [Abstract][Full Text] [Related]
13. Phenotypic and functional characterization of a bortezomib-resistant multiple myeloma cell line by flow and mass cytometry.
Baughn LB; Sachs Z; Noble-Orcutt KE; Mitra A; Van Ness BG; Linden MA
Leuk Lymphoma; 2017 Aug; 58(8):1931-1940. PubMed ID: 27981867
[TBL] [Abstract][Full Text] [Related]
14. Lanthanide-Coordinated Semiconducting Polymer Dots Used for Flow Cytometry and Mass Cytometry.
Wu X; DeGottardi Q; Wu IC; Yu J; Wu L; Ye F; Kuo CT; Kwok WW; Chiu DT
Angew Chem Int Ed Engl; 2017 Nov; 56(47):14908-14912. PubMed ID: 28941061
[TBL] [Abstract][Full Text] [Related]
15. Simplified mass cytometry protocol for in-plate staining, barcoding, and cryopreservation of human PBMC samples in clinical trials.
Abrecht C; Hallisey M; Dennis J; Nazzaro M; Brainard M; Hathaway E; Schork AN; Hodi FS; Severgnini M; Baginska J
STAR Protoc; 2022 Jun; 3(2):101362. PubMed ID: 35573480
[TBL] [Abstract][Full Text] [Related]
16. Normalization of mass cytometry data with bead standards.
Finck R; Simonds EF; Jager A; Krishnaswamy S; Sachs K; Fantl W; Pe'er D; Nolan GP; Bendall SC
Cytometry A; 2013 May; 83(5):483-94. PubMed ID: 23512433
[TBL] [Abstract][Full Text] [Related]
17. Mass cytometry: a highly multiplexed single-cell technology for advancing drug development.
Atkuri KR; Stevens JC; Neubert H
Drug Metab Dispos; 2015 Feb; 43(2):227-33. PubMed ID: 25349123
[TBL] [Abstract][Full Text] [Related]
18. Minimal Residual Disease Assessment in Multiple Myeloma by Multiparametric Flow Cytometry.
Rihova L; Vsianska P; Bezdekova R; Kralova R; Penka M; Krejci M; Pour L; Hájek R
Klin Onkol; 2017; 30(Supplementum2):21-28. PubMed ID: 28903567
[TBL] [Abstract][Full Text] [Related]
19. Characterizing Phenotypes and Signaling Networks of Single Human Cells by Mass Cytometry.
Leelatian N; Diggins KE; Irish JM
Methods Mol Biol; 2015; 1346():99-113. PubMed ID: 26542718
[TBL] [Abstract][Full Text] [Related]
20. Stabilizing Antibody Cocktails for Mass Cytometry.
Schulz AR; Baumgart S; Schulze J; Urbicht M; Grützkau A; Mei HE
Cytometry A; 2019 Aug; 95(8):910-916. PubMed ID: 31058420
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
